Enzyme induction in the elderly: Effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 5, 2000, Pages 512-520

  Dilger, Karin ^a   Hofmann, Ute ^b   Klotz, Ulrich ^b  

^a Dr Margarete F B I fur K P   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROPAFENONE; RIFAMPICIN;

AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG DISPOSITION; DRUG METABOLISM; ENZYME INDUCTION; ENZYME METABOLISM; GERIATRIC PATIENT; HUMAN; PRIORITY JOURNAL; QRS COMPLEX;

EID: 0034035056     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.106872     Document Type: Article

References (37)

1. 1. Reidenberg MM. Drug interactions and the elderly. J Am Geriatr Soc 1982;30:S67-8.
2. 2. Parker BM, Cusack BJ, Vestal RE. Pharmacokinetic optimisation of drug therapy in elderly patients. Drugs Aging 1995;7:10-8.
3. 3. Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging 1998;12:485-94.
4. 4. Salem SAM, Rajjayabun P, Shepherd AMM, Stevenson IH. Reduced induction of drug metabolism in the elderly. Age Aging 1978;7:68-73.
5. 5. Wood AJ, Vestal RE, Wilkinson GR, Branch RA, Shand DG. Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination. Clin Pharmacol Ther 1979;26:16-20.
6. 6. Twum-Barima T, Finnigan T, Habash AI, Cape RDT, Carruthers SG. Impaired enzyme induction by rifampicin in the elderly. Br J Clin Pharmacol 1984;17:595-7.
7. 7. Kinirons MT, Crome P. Clinical pharmacokinetic considerations in the elderly. Clin Pharmacokinet 1997;33:302-12.
8. 8. Turnheim K. Drug dosage in the elderly: is it rational? Drugs Aging 1998;13:357-79.
9. 9. Schmucker DL, Woodhouse KW, Wang RK, Wynne H, James OF, McManus M, et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 1990;48:365-74.
10. 10. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992;44:275-83.
11. 11. George J, Byth K, Farrell GC. Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol 1995;50: 727-30.
12. 12. Sotaniemi EA, Arranto AJ, Pelkonen O, Fasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997;61:331-9.
13. 13. Greenblatt DJ, Shader RI, Harmatz JS. Implications of altered drug disposition in the elderly: studies of benzodiazepines. J Clin Pharmacol 1989;29:866-72.
14. 14. Herd B, Wynne H, Wright P, James O, Woodhouse K. The effect of age on glucuronidation and sulphation of paracetamol in human liver fractions. Br J Clin Pharmacol 1991;32:768-70.
15. 15. Miners JO, Mackenzie PI. Drug glucuronidation in humans. Pharmacol Ther 1991;51:347-69.
16. 16. Kroemer HK, Klotz U. Glucuronidation of drugs: a reevaluation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmacokinet 1992;23:292-310.
17. 17. Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35:361-90.
18. 18. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A, et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997;7: 255-69.
19. 19. Kroemer HK, Mikus G, Kronbach T, Meyer UA, Eichelbaum M. In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther 1989;45:28-33.
20. 20. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol 1993;43:120-6.
21. 21. Siddoway LA, Roden DM, Woosley RL. Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations. Am J Cardiol 1984; 54:9D-12D.
22. 22. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Moerike K, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998;8:15-26.
23. 23. Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, Eichelbaum M. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolisers of CYP2D6. Pharmacogenetics 1999;9:551-9.
24. 24. Heinzel G, Woloszczak R, Thomann P. TopFit version 2.0: pharmacokinetic and pharmacodynamic data analysis system for the PC. New York: Gustav Fischer; 1993.
25. 25. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989;9:297-301.
26. 26. Hollmann M, Brode E, Hotz D, Kaumeier S, Kehrhan OH. Investigations on the pharmacokinetics of propafenone in man. Drug Res 1983:33:763-70.
27. 27. Hege HG, Hollmann M, Kaumeier S, Lietz H. The metabolic fate of 2H-labelled propafenone in man. Eur J Drug Metab Pharmacokinet 1984;9:41-55.
28. 28. De Wildt SN, Kearns GL, Leeder JS, Van den Anker JN. Glucuronidation in humans: pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999;36:439-52.
29. 29. Fromm MF, Dilger K, Busse D, Kroemer HK, Eichelbaum M, Klotz U. Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction. Br J Clin Pharmacol 1998;48:247-55.
30. 30. Caraco Y, Sheller J, Wood AJJ. Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects. J Pharmacol Exp Ther 1997;281:330-6.
31. 31. Bock KW, Wiltfang J, Blume R, Ullrich D, Bircher J. Paracetamol as a test drug to determine glucuronide formation in man. Effects of inducers and of smoking. Eur J Clin Pharmacol 1987;31:677-83.
32. 32. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49:311-8.
33. 33. Chiba P, Ecker G, Schmid D, Drach J, Tell B, Goldenberg S, et al. Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance. Mol Pharmacol 1996;49:1122-30.
34. 34. Zhou HH, Anthony LB, Wood JJ, Wilkinson GR. Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol 1990;30:471-5.
35. 35. Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994;55:402-11.
36. 36. Haemmerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokinet 1998;35:49-64.
37. 37. Smith DA, Chandler MHH, Shedlofsky SI, Wedlund PJ, Blouin RA. Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. Br J Clin Pharmacol 1991;32:735-9.